CN114008028A - 抑制癌细胞生长的嘧啶衍生物及其医药用途 - Google Patents
抑制癌细胞生长的嘧啶衍生物及其医药用途 Download PDFInfo
- Publication number
- CN114008028A CN114008028A CN202080044951.2A CN202080044951A CN114008028A CN 114008028 A CN114008028 A CN 114008028A CN 202080044951 A CN202080044951 A CN 202080044951A CN 114008028 A CN114008028 A CN 114008028A
- Authority
- CN
- China
- Prior art keywords
- amino
- phenyl
- pyrimidin
- dimethylamino
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000005907 cancer growth Effects 0.000 title abstract description 5
- 150000003230 pyrimidines Chemical class 0.000 title description 5
- 230000002401 inhibitory effect Effects 0.000 title description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 74
- -1 pyrimidine derivative compounds Chemical class 0.000 claims abstract description 48
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims abstract description 29
- 201000005202 lung cancer Diseases 0.000 claims abstract description 29
- 208000020816 lung neoplasm Diseases 0.000 claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 125000000217 alkyl group Chemical group 0.000 claims description 29
- 102000001301 EGF receptor Human genes 0.000 claims description 26
- 108060006698 EGF receptor Proteins 0.000 claims description 26
- 230000035772 mutation Effects 0.000 claims description 17
- 239000000126 substance Substances 0.000 claims description 16
- 239000001257 hydrogen Substances 0.000 claims description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 15
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 11
- 150000002367 halogens Chemical class 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 8
- 125000004432 carbon atom Chemical group C* 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 4
- ACUYNNSPLWYGMN-UHFFFAOYSA-N CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=NC(=C2)NC3=CC=CC=C3N(C)S(=O)(=O)C)OC Chemical compound CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=NC(=C2)NC3=CC=CC=C3N(C)S(=O)(=O)C)OC ACUYNNSPLWYGMN-UHFFFAOYSA-N 0.000 claims description 3
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims description 2
- 150000004885 piperazines Chemical group 0.000 claims description 2
- HONBMWNLNOMFNG-UHFFFAOYSA-N CC(C)OC(=O)C1=CN=C(N=C1NC2=CC=CC=C2N(C)S(=O)(=O)C)NC3=C(C=C(C(=C3)NC(=O)C=C)N(C)CCN(C)C)OC Chemical compound CC(C)OC(=O)C1=CN=C(N=C1NC2=CC=CC=C2N(C)S(=O)(=O)C)NC3=C(C=C(C(=C3)NC(=O)C=C)N(C)CCN(C)C)OC HONBMWNLNOMFNG-UHFFFAOYSA-N 0.000 claims 1
- XBMBKZWGCSGRAE-UHFFFAOYSA-N CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=C(C(=N2)NC3=CC=CC=C3N(C)S(=O)(=O)C)C(=O)OC4CC4)OC Chemical compound CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=C(C(=N2)NC3=CC=CC=C3N(C)S(=O)(=O)C)C(=O)OC4CC4)OC XBMBKZWGCSGRAE-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 10
- 238000006243 chemical reaction Methods 0.000 description 64
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 34
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 28
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 210000004027 cell Anatomy 0.000 description 20
- 238000002360 preparation method Methods 0.000 description 20
- 238000005160 1H NMR spectroscopy Methods 0.000 description 19
- 239000002904 solvent Substances 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 11
- 206010028980 Neoplasm Diseases 0.000 description 11
- 238000004128 high performance liquid chromatography Methods 0.000 description 11
- 239000012044 organic layer Substances 0.000 description 11
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 238000009472 formulation Methods 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- 239000003826 tablet Substances 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 238000004440 column chromatography Methods 0.000 description 8
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 7
- 125000000753 cycloalkyl group Chemical group 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 5
- AGWMJKGGLUJAPB-UHFFFAOYSA-N aluminum;dicalcium;iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[O-2].[O-2].[Al+3].[Ca+2].[Ca+2].[Fe+3] AGWMJKGGLUJAPB-UHFFFAOYSA-N 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 235000019439 ethyl acetate Nutrition 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000007911 parenteral administration Methods 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 125000000714 pyrimidinyl group Chemical group 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 4
- 238000011200 topical administration Methods 0.000 description 4
- 125000005917 3-methylpentyl group Chemical group 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- MJBWDEQAUQTVKK-IAGOWNOFSA-N aflatoxin M1 Chemical compound C=1([C@]2(O)C=CO[C@@H]2OC=1C=C(C1=2)OC)C=2OC(=O)C2=C1CCC2=O MJBWDEQAUQTVKK-IAGOWNOFSA-N 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000003111 delayed effect Effects 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 125000002950 monocyclic group Chemical group 0.000 description 3
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- FXOZQLLKDANSAF-UHFFFAOYSA-N CN(C)CCN(C)C1=CC(=C(C=C1N)NC2=NC=NC(=C2)NC3=CC=CC=C3N(C)S(=O)(=O)C)OC Chemical compound CN(C)CCN(C)C1=CC(=C(C=C1N)NC2=NC=NC(=C2)NC3=CC=CC=C3N(C)S(=O)(=O)C)OC FXOZQLLKDANSAF-UHFFFAOYSA-N 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- COKBOTNXAUSVCA-UHFFFAOYSA-N N-[2-[[6-(4-fluoro-2-methoxy-5-nitroanilino)pyrimidin-4-yl]amino]phenyl]-N-methylmethanesulfonamide Chemical compound CN(C1=CC=CC=C1NC2=CC(=NC=N2)NC3=CC(=C(C=C3OC)F)[N+](=O)[O-])S(=O)(=O)C COKBOTNXAUSVCA-UHFFFAOYSA-N 0.000 description 2
- SMPHLWMYOJCNDU-UHFFFAOYSA-N N-[2-[[6-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-nitroanilino]pyrimidin-4-yl]amino]phenyl]-N-methylmethanesulfonamide Chemical compound CN(C)CCN(C)C1=C(C=C(C(=C1)OC)NC2=NC=NC(=C2)NC3=CC=CC=C3N(C)S(=O)(=O)C)[N+](=O)[O-] SMPHLWMYOJCNDU-UHFFFAOYSA-N 0.000 description 2
- 239000007832 Na2SO4 Substances 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium on carbon Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 125000002785 azepinyl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 125000002837 carbocyclic group Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 2
- 229960001433 erlotinib Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 2
- 229960002584 gefitinib Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 208000037819 metastatic cancer Diseases 0.000 description 2
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000000869 mutational effect Effects 0.000 description 2
- YPMKIXADVWKELK-UHFFFAOYSA-N n-(2-aminophenyl)-n-methylmethanesulfonamide Chemical compound CS(=O)(=O)N(C)C1=CC=CC=C1N YPMKIXADVWKELK-UHFFFAOYSA-N 0.000 description 2
- MXWUQRNCQCAURO-UHFFFAOYSA-N n-methyl-n-(2-nitrophenyl)methanesulfonamide Chemical compound CS(=O)(=O)N(C)C1=CC=CC=C1[N+]([O-])=O MXWUQRNCQCAURO-UHFFFAOYSA-N 0.000 description 2
- UHNHTTIUNATJKL-UHFFFAOYSA-N n-methylmethanesulfonamide Chemical compound CNS(C)(=O)=O UHNHTTIUNATJKL-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- MEJYDZQQVZJMPP-ULAWRXDQSA-N (3s,3ar,6r,6ar)-3,6-dimethoxy-2,3,3a,5,6,6a-hexahydrofuro[3,2-b]furan Chemical compound CO[C@H]1CO[C@@H]2[C@H](OC)CO[C@@H]21 MEJYDZQQVZJMPP-ULAWRXDQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 description 1
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- WZIPUOGPHYXGLO-UHFFFAOYSA-N 2,4,5-trichloro-2H-pyran Chemical compound ClC(C=C1Cl)OC=C1Cl WZIPUOGPHYXGLO-UHFFFAOYSA-N 0.000 description 1
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- INUNLMUAPJVRME-UHFFFAOYSA-N 3-chloropropanoyl chloride Chemical compound ClCCC(Cl)=O INUNLMUAPJVRME-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-dimethylaminophenol Chemical compound CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 1
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 1
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-dimethylaminopyridine Substances CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- QVFMKXLCBIFOLL-UHFFFAOYSA-N CC(C)NC1=CC(=C(C=C1N(C)CCN(C)C)OC)NC2=NC3=C(C(=N2)NC4=CC=CC=C4N(C)S(=O)(=O)C)SC=C3 Chemical compound CC(C)NC1=CC(=C(C=C1N(C)CCN(C)C)OC)NC2=NC3=C(C(=N2)NC4=CC=CC=C4N(C)S(=O)(=O)C)SC=C3 QVFMKXLCBIFOLL-UHFFFAOYSA-N 0.000 description 1
- PYRMCIJBWPAUQP-UHFFFAOYSA-N CC(C)NC1=CC(=C(C=C1N2CCC(CC2)N(C)C)OC)NC3=NC=C(C(=N3)NC4=CC=CC=C4N(C)S(=O)(=O)C)Cl Chemical compound CC(C)NC1=CC(=C(C=C1N2CCC(CC2)N(C)C)OC)NC3=NC=C(C(=N3)NC4=CC=CC=C4N(C)S(=O)(=O)C)Cl PYRMCIJBWPAUQP-UHFFFAOYSA-N 0.000 description 1
- QJVGFHHPOFXBHY-UHFFFAOYSA-N CC(C)NC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)C)OC)NC4=NC5=C(C(=N4)NC6=CC=CC=C6N(C)S(=O)(=O)C)SC=C5 Chemical compound CC(C)NC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)C)OC)NC4=NC5=C(C(=N4)NC6=CC=CC=C6N(C)S(=O)(=O)C)SC=C5 QJVGFHHPOFXBHY-UHFFFAOYSA-N 0.000 description 1
- ZCRPXNPUSKWFCZ-UHFFFAOYSA-N CC(C)NC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)C)OC)NC4=NC=C(C(=N4)NC5=CC=CC=C5N(C)S(=O)(=O)C)Cl Chemical compound CC(C)NC1=CC(=C(C=C1N2CCC(CC2)N3CCN(CC3)C)OC)NC4=NC=C(C(=N4)NC5=CC=CC=C5N(C)S(=O)(=O)C)Cl ZCRPXNPUSKWFCZ-UHFFFAOYSA-N 0.000 description 1
- GSAYVGUVYBKTGK-UHFFFAOYSA-N CN(C)C1CCN(CC1)C2=CC(=C(C=C2NC(=O)C=C)NC3=NC4=C(C(=N3)NC5=CC=CC=C5N(C)S(=O)(=O)C)SC=C4)OC Chemical compound CN(C)C1CCN(CC1)C2=CC(=C(C=C2NC(=O)C=C)NC3=NC4=C(C(=N3)NC5=CC=CC=C5N(C)S(=O)(=O)C)SC=C4)OC GSAYVGUVYBKTGK-UHFFFAOYSA-N 0.000 description 1
- NOPFTRTVKLLWPD-UHFFFAOYSA-N CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC3=C(C(=N2)NC4=CC=CC=C4N(C)S(=O)(=O)C)SC=C3)OC Chemical compound CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC3=C(C(=N2)NC4=CC=CC=C4N(C)S(=O)(=O)C)SC=C3)OC NOPFTRTVKLLWPD-UHFFFAOYSA-N 0.000 description 1
- LSOBFUSWTPQZHB-UHFFFAOYSA-N CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=C(C(=N2)NC3=C(C4=NC=CN=C4C=C3)N(C)S(=O)(=O)C)Cl)OC Chemical compound CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=C(C(=N2)NC3=C(C4=NC=CN=C4C=C3)N(C)S(=O)(=O)C)Cl)OC LSOBFUSWTPQZHB-UHFFFAOYSA-N 0.000 description 1
- JOVJNHPXIUYCEF-UHFFFAOYSA-N CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=C(C(=N2)NC3=C(C4=NC=CN=C4C=C3)NS(=O)(=O)C)Cl)OC Chemical compound CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=C(C(=N2)NC3=C(C4=NC=CN=C4C=C3)NS(=O)(=O)C)Cl)OC JOVJNHPXIUYCEF-UHFFFAOYSA-N 0.000 description 1
- JYZKBZRGUWPHBH-UHFFFAOYSA-N CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=C(C(=N2)NC3=C(C=CC(=C3)F)N(C)S(=O)(=O)C)Cl)OC Chemical compound CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=C(C(=N2)NC3=C(C=CC(=C3)F)N(C)S(=O)(=O)C)Cl)OC JYZKBZRGUWPHBH-UHFFFAOYSA-N 0.000 description 1
- QXRVTVVQTULQLX-UHFFFAOYSA-N CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=C(C(=N2)NC3=C(C=CC(=C3)F)NS(=O)(=O)C)Cl)OC Chemical compound CN(C)CCN(C)C1=CC(=C(C=C1NC(=O)C=C)NC2=NC=C(C(=N2)NC3=C(C=CC(=C3)F)NS(=O)(=O)C)Cl)OC QXRVTVVQTULQLX-UHFFFAOYSA-N 0.000 description 1
- XSYVRXQUUBHRDT-UHFFFAOYSA-N CN(C1=CC=CC=C1NC2=CC(=NC=N2)Cl)S(=O)(=O)C Chemical compound CN(C1=CC=CC=C1NC2=CC(=NC=N2)Cl)S(=O)(=O)C XSYVRXQUUBHRDT-UHFFFAOYSA-N 0.000 description 1
- TVLCVXZOBCMBEC-UHFFFAOYSA-N CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3NC(=O)C=C)NC4=NC5=C(C(=N4)NC6=CC=CC=C6N(C)S(=O)(=O)C)SC=C5)OC Chemical compound CN1CCN(CC1)C2CCN(CC2)C3=CC(=C(C=C3NC(=O)C=C)NC4=NC5=C(C(=N4)NC6=CC=CC=C6N(C)S(=O)(=O)C)SC=C5)OC TVLCVXZOBCMBEC-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- ZHTYVRHEHQPWGW-UHFFFAOYSA-N N-[2-[[2-[4-[4-(dimethylamino)piperidin-1-yl]-2-methoxy-5-(propan-2-ylamino)anilino]thieno[3,2-d]pyrimidin-4-yl]amino]phenyl]-N-methoxymethanesulfonamide Chemical compound CC(C)NC(C(N(CC1)CCC1N(C)C)=C1)=CC(NC(N=C2NC(C=CC=C3)=C3N(OC)S(C)(=O)=O)=NC3=C2SC=C3)=C1OC ZHTYVRHEHQPWGW-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000001448 anilines Chemical class 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 125000003828 azulenyl group Chemical group 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- XJGKOZJLGWXKHV-UHFFFAOYSA-N cyclopropyl pyrimidine-5-carboxylate Chemical compound C=1N=CN=CC=1C(=O)OC1CC1 XJGKOZJLGWXKHV-UHFFFAOYSA-N 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 229940075557 diethylene glycol monoethyl ether Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229940121647 egfr inhibitor Drugs 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 229960003720 enoxolone Drugs 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000017095 negative regulation of cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 description 1
- 229940032159 propylene carbonate Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000002053 thietanyl group Chemical group 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 125000005023 xylyl group Chemical group 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
本发明提供了抑制癌细胞生长的新型嘧啶衍生物化合物及其药学上可接受的盐。本发明提供了一种包含这些化合物或其药学上可接受的盐的药物组合物。本发明还提供了一种治疗肺癌的医疗用途，其特征在于使用这些嘧啶衍生物化合物及其药学上可接受的盐作为活性成分。本发明还提供了一种治疗肺癌的方法，其包括施用根据本发明的化合物的有效剂量、其盐或包含它们的组合物。
Description
技术领域
本发明涉及有效抑制癌细胞生长的嘧啶衍生物化合物及其抗癌用途。
背景技术
在非小细胞肺癌患者中发现了表皮生长因子受体(EGFR)激酶域的各种突变为致癌基因，吉非替尼(Gefitinib)、厄洛替尼(Erlotinib)和奥希替尼(Osimertinib)等被用作表皮生长因子受体(EGFR)的小分子激酶抑制剂来治疗它们。
其中，由表皮生长因子受体外显子20插入突变(EGFR EXON 20Insertionmutation)引起的肺癌占所有突变的5％，各种表皮生长因子受体抑制剂(EGFRinhibitors)已被评估用于其治疗，但目前仍没有药物被批准作为治疗EGFR EXON 20插入突变肺癌的标准疗法，因此迫切需要开发一种可以治疗它的药物。
发明内容
相应地，本发明要解决的问题是提供对治疗肺癌，特别是对显示表皮生长因子受体突变特性的肺癌有用的化合物及其医药用途。
为了解决上述问题，本发明提供了以下化学式1的化合物或其药学上可接受的盐。
[化学式1]
在化学式1中，
A、B、D、E和G是A＝N、B＝C、D＝C、E＝C和G＝N的组合，或A＝N、B＝C、D＝N、E＝C和G＝C的组合，
W是氧或NH，
X和Y分别是CH、氧或氮，
当X或Y是氧时，Z1和Z2分别不存在，或当X或Y不是氧时，Z1和Z2分别是C1至C4烷基，或分别由碳原子组成并且相互连接以与X和Y一起形成5、6或7元环，
R1是C1至C4烷基，
R2是氢，或C1至C4烷基，
R3和R4分别是氢、卤素、OH、OMe、OEt、CN、CF3、C1至C4烷基或相互连接以形成5或6元(与苯基融合)杂芳环，且
R5是氢、卤素、OH、OMe、OEt、CN、CF3或C1至C4烷基，
R6和R7分别是氢、卤素、OH、OMe、OEt、CN、CF3、COOH、COO-C1-4烷基、COO-C1-5环烷基、C1至C4烷基或相互连接以形成5或6元杂芳环，R8是氢、卤素、OH、OMe、OEt、CN、CF3或C1至C4烷基，
R9是-C(O)-CH＝CH2或C1至C4烷基，并且
R10不存在或是氢、卤素、C1至C4烷基、OH、OMe、OEt、CN、CF3、NMe2、哌嗪、被C1至C3烷基取代的哌嗪、吗啉或被C1至C3烷基取代的吗啉。
本发明人已经证实，根据本发明的新型化合物对治疗肺癌是有效的，尤其是对显示有表皮生长因子受体突变的肺癌。特别地，本发明的化合物对治疗具有肺癌中显示表皮生长因子受体(EGFR)EXON 20插入突变特性的癌细胞的肺癌是有用的。
如本文所使用的术语”烷基”是指具有1至10个碳原子的饱和直链或支链非环状碳氢化合物(当碳原子的数量没有特别限制时)。“低级烷基”是指具有1至4个碳原子的直链或支链烷基。有代表性的饱和直链烷基包括：-甲基、-乙基、-正丙基、-正丁基、-正戊基、-正己基、-正庚基、-正辛基、-正壬基和-正癸基，而饱和支链烷基包括：-异丙基、-仲丁基、-异丁基、-叔丁基、异戊基、2-甲基己基、3-甲基丁基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2-甲基己基、3-甲基己基、2-甲基戊基、3-甲基戊基、4-甲基戊基、2-甲基己基、3-甲基己基、4-甲基己基、5-甲基己基、2,3-二甲基丁基、2,3-二甲基戊基、2,4-二甲基戊基、2,3-二甲基己基、2,4-二甲基己基、2,5-二甲基己基、2,2-二甲基戊基、2,2-二甲基己基、3,3-二甲基戊基、3,3-二甲基己基、4,4-二甲基己基、2-乙基戊基、3-乙基戊基、2-乙基己基、3-乙基己基、4-乙基己基、2-甲基-2-乙基戊基、2-甲基-3-乙基戊基、2-甲基-4-乙基戊基、2-甲基-2-乙基己基、2-甲基-3-乙基己基、2-甲基-4-乙基己基、2,2-二乙基戊基、3,3-二乙基己基、2,2-二乙基己基和3,3-二乙基己基。
如本文所使用的术语“环烷基”是指具有碳原子和氢原子且不具有碳-碳多键的单环或多环饱和环。环烷基的实例包括(C3-C7)环烷基(例如，环丙基、环丁基、环戊基、环己基和环庚基)，但不限于此。在本发明的一个方面，环烷基是(C3-C5)环烷基。在本发明的另一个方面，环烷基是环丙基。在一个实例中，环烷基团是单环或双环。
在此，当描述为“C1-6”或“C1至C6”时，这意味着碳原子的数量为1至6。例如，C1-6烷基是指具有1至6个碳原子的烷基。
如本文所使用的术语“卤素”和“卤”是指氟、氯、溴或碘。
如本文所使用的术语“芳基”是指含有5至10个环原子的碳环芳基团。代表性的实例包括苯基、甲苯基、二甲苯基、萘基、四氢萘基、蒽基、芴基、茚基和薁基等，但不限于此。碳环芳基团可以被选择性地取代。
如本文所使用的“杂芳基”是5至10元杂环芳烃环，其有至少一个选自由氮、氧和硫所组成的组的至少一个杂原子，是包括至少一个碳原子和具有单环和双环系统的5-10元杂环芳环。代表性的杂芳基是三唑基、四唑基、噁二唑基、吡啶基、呋喃基、苯并呋喃基、苯硫基(thiophenyl)、苯并苯硫基(benzothiophenyl)、喹啉基、吡咯基、吲哚基、噁唑基、苯并噁唑基、咪唑基、苯并咪唑基、噻唑基、苯并噻唑基、异噁唑基、吡唑基、异噻唑基、哒嗪基、嘧啶基(pyrimidinyl)、吡嗪基、三嗪基、噌啉基、酞嗪基、喹唑啉基、嘧啶基(pyrimidyl)、氧杂环丁烷基、吖庚因基(azepinly)、哌嗪基、吗啉基、二噁烷基、噻丁基(thietanyl)和噁唑基。
在本文中，化学式1所代表的化合物可以以无机酸或有机酸诱导的盐的形式使用，例如，它可以以盐的形式使用，盐选自由盐酸、氢溴酸、硫酸、磷酸、硝酸、乙酸、乙醇酸、乳酸、丙二酸、琥珀酸、戊二酸、富马酸、苹果酸、酒石酸、柠檬酸、甘道夫酸、乳酸、丙酮酸、丙二酸、琥珀酸、戊二酸、富马酸、苹果酸、扁桃酸、酒石酸、柠檬酸、抗坏血酸、棕榈酸、马来酸、苯甲酸、羟基苯甲酸、苯乙酸、肉桂酸、水杨酸、甲磺酸、乙磺酸、苯磺酸、甲苯磺酸等所组成的组中的一种或多种酸诱导。
如本文所使用的术语“本发明的化合物”是指化学式1的每种化合物，以及包合物、水合物、溶剂合物或其多晶型物物。此外，术语“本发明的化合物”的意思是本发明化合物的药学上可接受的盐，除非提及其药学上可接受的盐。在一个实例中，本发明的化合物可以作为立体异构纯化合物(例如，基本上不含其他立体异构体(例如，85％ee或以上，90％ee或以上，95％ee或以上，97％ee或以上，或99％ee或以上))存在。换句话说，当根据本发明的化学式1的化合物或其盐是互变异构体和/或立体异构体(例如几何异构体和构象异构体)时，它们的每个分离异构体和混合物也包括在本发明的化合物的范围内。当本发明的化合物或其盐在其结构中具有不对称碳时，它们的旋光化合物和外消旋混合物也包括在本发明化合物的范围内。
如本文所使用的术语“多晶型物”是指本发明的化合物或其复合物的固体结晶形式。同一化合物的不同多晶型物表现出不同的物理、化学和/或光谱特性。物理特性的差异包括稳定性(如，热稳定性或光稳定性)、压缩性和密度(对配方和产品制备很重要)以及溶解率(可能影响生物药效率)，但不限于此。稳定性的差异会引起化学反应性的变化(如，不同的氧化，例如由一种多晶型物组成时比由另一种多晶型物组成时变色更快)或机械性能的变化(如，储存为动力学上优选的多晶型物的纯化碎片被转化为热力学上更稳定的多晶型物)或其两者的变化(纯化的一种多晶型物对高湿度下的降解更敏感)。多晶型物的其他物理特性可能影响它们的加工。例如，一种多晶型物可能比另一种多晶型物更容易形成溶剂合物，例如，由于其形状或粒子大小分布，其可能更难过滤或洗涤。
如本文所使用的术语“溶剂化合物”是指本发明的化合物或其药学上可接受的盐，包括由非共价分子间力结合的化学或非化学计算量的溶剂。优选溶剂是挥发性的，无毒的，可对人类进行微量施用。
如本文所使用的术语“水合物”是指本发明的化合物或其药学上可接受的盐，包括由非共价分子间作用力结合的化学或非化学计算量的水。
如本文所使用的术语“包合物”是指本发明的化合物或其盐以晶格形式存在，其晶格形式含有限制客体分子(例如溶剂或水)的空间(例如通道)。
如本文所使用的术语“纯化”是指分离物在分离时至少有90％的纯度，在一个实例中，它是指95％或更高的纯度，在另一个实例中，它是指99％或更高的纯度，在其他实例中，它是指99.9％或更高的纯度。
如本文所使用的“治疗”包括根除、移除、改变或控制原发性、局部或转移性癌组织；以及最大限度地减少或延迟癌症的扩散。
非限制性的，根据本发明的化合物的实例包括以下化合物及其药学上可接受的盐。
-N-(2-((5-氯-2-((4-((2-(二甲基氨基)乙基)(甲基)氨基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)吡啶-4-基)氨基)苯基)-N-甲磺酸酰胺，
-N-(2-((2-((4-((2-(二甲基氨基)乙基)(甲基)氨基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)噻吩并[3,2-d]嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺，
-N-(2-((2-((4-(4-(二甲基氨基)哌啶-1-基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)噻吩并[3,2-d]嘧啶-4-基)氨基)苯基)-N-甲氧基甲磺酰胺，
-N-(2-((2-((5-(异丙基氨基)-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)噻吩并[3,2-d]嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺，
-N-(2-((5-氯-2-((5-(异丙基氨基)-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺，
-N-(2-((5-氯-2-((4-(4-(二甲基氨基)哌啶-1-基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺，
-N-(4-甲氧基-5-((4-((2-(N-甲基甲磺酰氨基)苯基)氨基)噻吩并[3,2-d]嘧啶-2-基)氨基)-2-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)丙烯酰胺，
-N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基-5-((4-((2-(N-甲基甲磺酰氨基)苯基)氨基)噻吩并[3,2-d]嘧啶-2-基)氨基)苯基)丙烯酰胺，
-N-(2-(4-(二甲基氨基)哌啶-1-基)-4-甲氧基-5-((4-((2-(N-甲基甲磺酰氨基)苯基)氨基)噻吩并[3,2-d]嘧啶-2-基)氨基)苯基)丙烯酰胺，
-N-(5-((5-氯-4-((2-(甲磺酰氨基)苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺，
-N-(5-((5-氯-4-((5-(N-甲基甲磺酰氨基)喹喔啉-6-基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺，
-N-(5-((5-氯-4-((5-(甲磺酰氨基)喹喔啉-6-基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺，
-N-(5-((5-氯-4-((5-氟-2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺，
-N-(5-((5-氯-4-((5-氟-2-(甲磺酰氨基)苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺，
-2-((5-丙烯酰胺基-4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基苯基)氨基)-4-((2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-5-羧酸异丙酯，
-2-((5-丙烯酰胺基-4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基苯基)氨基)-4-((2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-5-羧酸环丙酯，或
N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基-5-((6-((2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-4-基)氨基)苯基)丙烯酰胺。
在另一个方面，本发明提供了一种药物组合物，包括化学式1的化合物的治疗有效剂量或根据本发明的其药学上可接受的盐，以及药学上可接受的载体。
如本文所使用的“有效剂量”是指足以破坏、改变、控制或清除原发性、局部或转移性癌细胞或癌组织的本发明的化合物的量；减缓或尽量减少癌症的扩散；或在治疗或管理癌症、肿瘤性疾病或肿瘤中提供治疗益处。“有效剂量”也指足以导致癌症或肿瘤细胞死亡的本发明的化合物的量。“有效剂量”也指足以在体外或体内抑制或降低肺癌细胞活性的量。
在另一个方面，本发明提供了一种治疗疾病或病症的方法，包括向需要的受试者施用治疗有效剂量的化学式1的化合物或其药学上可接受的盐，并且该疾病或病症是肺癌。在另一个方面，该受试者是人。在另一个方面，该肺癌是显示表皮生长因子受体(EGFR)突变特性的肺癌。在另一方面，该肺癌是具有显示表皮生长因子受体EXON 20插入突变(EGFREXON 20插入突变)特性的癌细胞的肺癌。
换句话说，本发明提供了一种医疗用途，其特征是将根据本发明的化学式1的化合物或其药学上可接受的盐作为活性成分。在一个方面，本发明的医疗用途是用于治疗或预防本文所述的疾病或病症的用途。
因此，在另一个方面，本发明提供了一种药物组合物，其用于治疗或预防肺癌，特别是表皮生长因子受体突变表达的肺癌，该药物组合物包括根据本发明的化合物或其药学上可接受的盐作为活性成分。
本发明的化合物或其药学上可接受的盐一般以治疗有效剂量进行给药。本发明的化合物可以通过任何适当的途径以适合该途径的药物组合物形式的有效剂量给药，并进行预期的治疗。有效剂量一般可以是约0.0001至约200mg/kg(体重)/天，最好是约0.001至约100mg/kg/天，通过单次或分次给药。根据年龄、物种和要治疗的疾病或病症，低于该范围下限的剂量水平可能是合适的。在其他情况下，可以使用更大的剂量而不产生有害的副作用。较大的剂量可以分成几个较小的剂量，在一天内施用。确定适当剂量的方法在本领域是众所周知的，例如，文件雷明顿(Remington):《药学的科学与实践》，麦克出版公司，第20版，2000可被使用。
对于肺癌的治疗，本文所述的化合物或其药学上可接受的盐可通过以下各种方法给药。
口服给药
本发明的化合物可以口服给药，口服是一个包括吞咽的概念。通过口服给药，本发明的化合物可以进入胃肠道，也可以直接从口腔吸收进入血流，例如口腔或舌下给药。
适合口服的组合物可以是固体、液体、凝胶或粉末的形式，可以有片剂、锭剂、胶囊、颗粒剂和粉末等配方。
用于口服的组合物可选择性地进行肠溶，并可通过肠溶表现出延迟或持续释放。换句话说，根据本发明的口服施用组合物可以是具有即时或改良释放模式的制剂。
该液体制剂可包括溶液、糖浆和悬浮液，该液体组合物可以是包含在软胶囊或硬胶囊中的形式。该制剂可包括药学上可接受的载体，例如，水、乙醇、聚乙二醇、纤维素或油。该制剂还可包括一种或多种乳化剂和/或悬浮剂。
在片剂中，作为活性成分的药物量可以基于片剂总重量的约0.05重量％至约95重量％，通常是约2重量％至约50重量％的量存在。此外，片剂可包括用量约为制剂的0.5重量％至约35重量％，通常是约为2重量％至约25重量％的崩解剂。作为崩解剂的实例，可以使用乳糖、淀粉、甘醇酸淀粉钠、聚乙烯聚吡咯烷酮、交联羧甲基纤维素钠、麦芽糊精或其混合物，但不限于此。
用于制备成片剂而组成的适当的助流剂(glydent)可以以约0.1重量％至约重量5％的量存在，且滑石、二氧化硅、硬脂酸、钙、锌或镁硬脂酸和硬脂酰富马酸钠等可用作助流剂，但本发明不受这些种类的添加剂限制。
作为制备成片剂的粘合剂，可使用明胶、聚乙二醇、糖、树胶、淀粉、聚乙烯吡咯烷酮、羟丙基纤维素和羟丙基甲基纤维素等。且作为制备成片剂的合适稀释剂，可使用甘露醇、木糖醇、乳糖、葡萄糖、蔗糖、山梨醇、淀粉和微晶纤维素等，但本发明不限于这些种类的添加剂。
可选择性地包含在片剂中的增溶剂的用量可为基于片剂总重量的约0.1重量％至约3重量％，例如，聚山梨酯、月桂硫酸钠、十二烷基硫酸钠、碳酸丙烯酯、二甘醇单乙醚、二甲基异山梨酯、聚氧乙烯甘醇酸化天然或氢化蓖麻油、HCORTM(Nikkol)。油酯、GelucireTM、辛酸/辛酸单/双甘油酯、山梨糖醇脂肪酸酯和Solutol HSTM等可用于根据本发明的药物组合物，但本发明不限于这些特定种类的增溶剂。
胃肠外给药
本发明的化合物可以直接给药到血液、肌肉或肠道。适当的胃肠外给药方法包括静脉内、肌肉内、皮下动脉内、腹腔内、鞘内和颅内注射等。合适的胃肠外给药装置包括注射器(包括针头和无针注射器)和输液方法。
用于胃肠外给药的组合物可以是具有即时或改良释放模式的制剂，且改良释放模式可以是延迟释放或持续释放模式。
大多数胃肠外制剂是液体组合物，这些液体组合物是包含根据本发明的药物成分、盐、缓冲剂和等渗剂等的水溶液。
胃肠外制剂也可以制备成干燥形式(例如冻干)或无菌非水溶液。这些制剂可与适当的载体如无菌水一起使用。溶解性增强剂也可用于制备胃肠外溶液。
局部给药
本发明的化合物可通过皮肤或经皮肤的方式进行局部给药。局部给药的制剂包括洗剂、溶液、乳膏、凝胶、水凝胶、软膏、泡沫、植入物和贴片等。用于局部给药制剂的药学上可接受的载体可包括水、酒精、矿物油、甘油和聚乙二醇等。局部给药也可以通过电穿孔、离子电渗疗法和声透疗法等方式进行。
用于局部给药的组合物可以是具有即时或改良释放模式的制剂，而改良释放模式可以是延迟或持续释放模式。
优势效果
本发明提供了具有癌细胞抑制活性的新的嘧啶衍生物化合物及其药学上可接受的盐。根据本发明的嘧啶衍生物或其药学上可接受的盐可以有效地抑制表皮生长因子受体突变表达的癌细胞的生长，特别是，存在于肺癌中的癌细胞。因此，根据本发明的化合物及其药学上可接受的盐对治疗肺癌是有用的。
具体实施方式
下面，为了帮助理解本发明，将通过实施例等对其进行详细描述。然而，根据本发明的实施例可以以各种其他形式进行修改，而且本发明的范围不应理解为仅限于以下实施例。提供本发明的实施例是为了向具有本发明所涉及领域的一般知识的人更完整地描述本发明。
根据本发明，上述化学式1所代表的化合物可以很容易地制备，例如，参照下面反应图式1、2、3和4所示方法。
[反应图式1]
[反应图式2]
[反应图式3]
[反应图式4]
合成实施例：合成N-(2-((5-氯-2-((4-((2-(二甲基氨基)乙基)(甲基)氨基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)吡啶-4-基)氨基)苯基)-N-甲磺酸酰胺和N-((5-氯-4-((2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-2-基)氨基-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺
步骤1：
在上述反应图式1中，将结构A1-P3(3g，21.262mmol)溶于乙腈(150mL)。在室温下，加入CS2CO3(10.4g，31.892mmol)和N-甲基甲磺酰胺，然后在80℃搅拌12小时。反应后剩余的固体被过滤，减压蒸馏除去有机溶剂，得到Al-P2。没有单独的分离过程，其被用于下一反应。
步骤2：
将步骤1中得到的结构A1-P2(4.5g，19.545mmol)溶解在MeOH(100mL)和DCM(50mL)的混合溶剂中，然后加入10％Pd/C(0.416g，3.909mmol)。在氢气环境下，搅拌2小时，然后用铁铝酸四钙过滤，减压蒸馏，除去溶剂，得到粗制A1-P1。该固体用乙醚和正戊烷洗涤，用于下一步反应，不需要单独的分离过程。
步骤3：
将前述反应得到的结构A1-P1(8.3g，41.446mmol)溶于IPA(200mL)，然后在室温下加入2,5,6-三氯嘧啶(12.163g，66.314mmol)和DIPEA(21.428g，166mmol)，在90℃搅拌12小时。反应完成后，减压蒸馏，除去溶剂，然后加水，用DCM提取。混合溶液再次用2N HCl洗涤，分离有机层并减压蒸馏，得到粗制A1。没有单独的分离过程，其被用于下一反应。
步骤4：
在上述反应图式2中，将结构B1-P5(4g，21.489mmol)溶于DCM(100mL)，然后在室温下，加入Boc酸酐(4.690g，21.489mmol)和DMAP(0.262g，2.149mmol)，并搅拌12小时。当反应完成后，反应混合物用2N HCl洗涤，然后用Na2SO4干燥并过滤，再减压蒸馏，得到粗制的B1-P4。采用柱色谱法，得到纯的B1-P4目标化合物(5.8g，97.5％)。
步骤5：
在上述反应图式2中，将结构B1-P4(2.2g，7.685mmol)溶于乙腈(50mL)，然后在室温下加入K2CO3(2.124g，15.371mmol)和N,N,N'-三甲基二胺，然后在80℃搅拌12小时。反应完成后，过滤反应产物，减压蒸馏，得到粗制B1-P3。没有单独的分离过程，其被用于下一反应。
步骤6：
在上述反应图式2中，将结构B1-P3(2.8g，7.6mmol)溶解在MeOH(50mL)和DCM(20mL)的混合溶剂中，在氢气环境下搅拌4小时。当反应完成后，用铁铝酸四钙过滤，减压蒸馏除去溶剂，得到粗制的B1-P2。没有单独的分离过程，其被用于下一反应。
步骤7：
在上述反应图式2中，向B1-P3(580.8mg，1.00mmol)中加入丙酮20mL，然后加入锌粉(653.9mg，10.0mmol)和饱和溶液NH4Cl(10mL)并在6小时回流下完成反应。在室温下冷却后，用铁铝酸四钙除去锌粉，减压除去溶剂，然后用EtOAc提取得到的水层。在得到的有机层中，在减压下除去溶剂，用柱色谱法进行纯化。
步骤8：
在上述反应图式2中，将B1-P1(300mg，0.764mmol)溶于DCM(15mL)，然后冷却到0℃。然后，加入TFA(0.6mL，7.643mmol)，并将温度提高到室温，搅拌3小时。反应完成后，减压蒸馏，除去溶剂，用DCM和饱和NaHCO3溶液清洗，然后将有机层分离并干燥，再减压蒸馏。没有单独的分离过程，其被用于下一反应。
步骤9：
在上述反应图式3中，将丙烯酸(75mg，1.034mmol)溶于DMF(4mL)，然后冷却到0℃。然后，加入HATU(393mg，1.034mmol)和DIPEA(400mg，3.103mmol)，再加入B1-P2(350mg，1.034mmol)，将反应物在室温下搅拌12小时。当反应完成后，用H2O和DCM提取。分离出的有机层用Na2SO4干燥，并过滤，然后减压蒸馏。使用柱色谱法，得到纯化得B1-P1目标化合物(220mg，55％)。
步骤10：
在上述反应图式3中，将C1-P1(300mg，0.764mmol)溶于DCM(15mL)，然后冷却到0℃。加入TFA(0.6mL，7.643mmol)，将温度升高到室温，搅拌3小时。反应完成后，减压蒸馏，除去溶剂，用DCM和饱和NaHCO3溶液洗涤，然后分离有机层，干燥，再减压蒸馏。没有单独的分离过程，其被用于下一反应。
步骤11：
在上述反应图式4中，将结构B1(50mg，0.178mmol)溶于异丙醇(3mL)，然后在室温下加入A1(71mg，0.205mmol)和PTSA(48.8mg，0.257mmol)，在90℃搅拌12小时。反应完成后，减压蒸馏，除去溶剂，用水和10％MeOH/DCM提取。分离有机层并干燥，减压蒸馏，得到粗制的化合物1。使用柱色谱法，得到纯化的化合物1(60mg，58％)。
1H NMR(400MHz；CDCl3):δ(ppm):8.26-8.49(2H,m),8.16(1H,s)8.09-8.08(1H,d),7.83(1H,s),7.55-7.52(1H,dd),6.98(1H,s),6.97-6.77(1H,dd),5.72(1H,dd),4.76(1H,m),3.67(3H,s),3.14(3H,s),3.06(3H,s),2.79(2H,m),2.70(3H,s),2.20(8H,br s),1.11(6H,d).[M+H]+:m/z 591.17实测592.2 HPLC纯度：97.9％
步骤12：
在上述反应方案4中，将结构C1(50mg，0.171mmol)溶于异丙醇(3mL)，然后在室温下加入A1(71mg，0.205mmol)和PTSA(49.1mg，0.258mmol)，在90℃搅拌12小时。反应完成后，减压蒸馏，除去溶剂，用水和10％MeOH/DCM提取。分离有机层并干燥，减压蒸馏，得到粗制的化合物12。使用柱色谱法，得到纯化的化合物12(65mg，63％)。
1H NMR(400MHz；CDCl3):δ(ppm):10.02(1H,br s),8.35-8.31(2H,m),8.26(1H,s)8.21-8.19(1H,d),8.09(1H,s),7.53-7.50(1H,dd),6.95(1H,s),6.18-6.14(1H,dd),5.72-5.68(1H,dd),4.31(1H,m),3.72(3H,s),3.14(3H,s),3.05(3H,s),2.86(2H,m),2.66(3H,s),2.19(8H,br s),1.12(6H,d).[M+H]+:m/z 591.17实测592.2 HPLC纯度：98.1％
实施例1.N-(2-((5-氯-2-((4-((2-(二甲基氨基)乙基)(甲基)氨基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)吡啶-4-基)氨基)苯基)-N-甲磺酸酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz；CDCl3):δ(ppm):8.26-8.49(2H,m),8.16(1H,s)8.09-8.08(1H,d),7.83(1H,s),7.55-7.52(1H,dd),6.98(1H,s),6.97-6.77(1H,dd),5.72(1H,dd),4.76(1H,m),3.67(3H,s),3.14(3H,s),3.06(3H,s),2.79(2H,m),2.70(3H,s),2.20(8H,br s),1.11(6H,d).[M+H]+:m/z 591.17实测592.2HPLC纯度：97.9％
实施例2.N-(2-((2-((4-((2-(二甲基氨基)乙基)(甲基)氨基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)噻吩并[3,2-d]嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ9.51(s,1H),9.20(s,1H),8.02(s,1H),7.63(d,J＝7.6Hz,1H),7.45(dd,J＝7.5,1.5Hz,1H),7.39-7.32(m,2H),7.04(td,J＝7.5,1.5Hz,1H),6.76(td,J＝7.5,1.5Hz,1H),6.46(s,1H),5.51(d,J＝8.4Hz,1H),4.31(m,1H),3.85(s,3H),3.44-3.34(bs,2H),3.32(s,3H),3.26(s,3H),3.00(s,3H),2.57-2.50(m,8H),1.12(d,J＝6.9Hz,6H).MS:ESI m/z 613.1[M+H]+HPLC纯度：99.0％
实施例3.N-(2-((2-((4-(4-(二甲基氨基)哌啶-1-基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)噻吩并[3,2-d]嘧啶-4-基)氨基)苯基)-N-甲氧基甲磺酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ9.51(s,1H),9.20(s,1H),8.02(s,1H),7.63(d,J＝7.6Hz,1H),7.45(dd,J＝7.5,1.5Hz,1H),7.39-7.32(m,2H),7.04(td,J＝7.5,1.5Hz,1H),6.76(td,J＝7.5,1.5Hz,1H),6.46(s,1H),5.51(d,J＝8.4Hz,1H),4.31(m,1H),3.72(s,3H),3.14(s,3H),3.06(s,3H),3.00(d,J＝11.2Hz,2H),2.62(dd,J＝12.4,10.2Hz,2H),2.19(m,8H),1.80(d,J＝11.4Hz,2H),1.65(q,J＝11.3Hz,2H),1.12(d,J＝6.9Hz,6H).MS:ESI m/z 639.0[M+H]+HPLC纯度：98.5％
实施例4.N-(2-((2-((5-(异丙基氨基)-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)噻吩并[3,2-d]嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ9.50(s,1H),9.22(s,1H),8.00(s,1H),7.61(d,J＝7.6Hz,1H),7.45(dd,J＝7.5,1.5Hz,1H),7.37-7.33(m,2H),7.04(td,J＝7.5,1.5Hz,1H),6.76(td,J＝7.5,1.5Hz,1H),6.46(s,1H),5.51(d,J＝8.4Hz,1H),4.32(m,1H),3.70(s,3H),3.15(s,3H),3.04(s,3H),3.01(d,J＝11.2Hz,2H),.69-2.57(m,2H),2.55-2.48(m,4H),2.25(m,5H),2.12(s,3H),1.81(d,J＝11.9Hz,2H),1.67(q,J＝11.4,10.7Hz,2H),1.10(d,J＝6.9Hz,6H).MS:ESI m/z 694.1[M+H]+HPLC纯度：97.9％
实施例5.N-(2-((5-氯-2-((5-(异丙基氨基)-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz；CDCl3):δ(ppm):10.02(1H,br s),8.35-8.31(2H,m),8.26(1H,s)8.21-8.19(1H,d),8.09(1H,s),7.53-7.50(1H,dd),6.95(1H,s),6.18-6.14(1H,dd),5.72-5.68(1H,dd),4.31(1H,m),3.72(s,3H),3.14(s,3H),3.06(s,3H),3.00(2H,d),2.69-2.57(2H,m),2.55-2.48(4H,m),2.25(5H,m),2.12(3H,s),1.81(2H,d),1.67(2H,q),1.12(d,6H).MS:ESI m/z 672.0[M+H]+HPLC纯度：98.2％
实施例6.N-(2-((5-氯-2-((4-(4-(二甲基氨基)哌啶-1-基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz；CDCl3):δ(ppm):10.02(1H,br s),8.37-8.33(2H,m),8.23(1H,s)8.20-8.17(1H,d),8.09(1H,s),7.53-7.50(1H,dd),6.95(1H,s),6.18-6.14(1H,dd),5.72-5.68(1H,dd),4.31(1H,m),3.72(s,3H),3.14(s,3H),3.06(s,3H),3.00(d,J＝11.2Hz,2H),2.62(2H,dd),2.19(8H,m),1.80(2H,d),1.65(2H,q),1.12(6H,d).MS:ESI m/z 617.0[M+H]+HPLC纯度：97.6％
实施例7.N-(4-甲氧基-5-((4-((2-(N-甲基甲磺酰氨基)苯基)氨基)噻吩并[3,2-d]嘧啶-2-基)氨基)-2-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)丙烯酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ10.05(s,1H),8.75(s,1H),8.36(s,1H),8.03(d,J＝5.3Hz,1H),8.00(dd,J＝8.1,1.6Hz,1H),7.70(s,1H),7.52(dd,J＝7.9,1.6Hz,1H),7.24(td,J＝7.7,1.6Hz,1H),7.20-7.11(m,2H),6.93(s,1H),6.37(m,1H),6.18(dd,J＝16.9,2.1Hz,1H),5.74-5.66(m,1H),3.72(s,3H),3.14(s,3H),3.06(s,3H),3.00(d,J＝11.2Hz,2H),2.69-2.57(m,2H),2.55-2.48(m,4H),2.25(m,5H),2.12(s,3H),1.81(d,J＝11.9Hz,2H),1.67(q,J＝11.4,10.7Hz,2H).MS:ESI m/z 706.2[M+H]+,HPLC纯度：98.5％.
实施例8.N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基-5-((4-((2-(N-甲基甲磺酰氨基)苯基)氨基)噻吩并[3,2-d]嘧啶-2-基)氨基)苯基)丙烯酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ10.03(s,1H),8.74(s,1H),8.36(s,1H),8.03(d,J＝5.3Hz,1H),8.00(dd,J＝8.1,1.6Hz,1H),7.71(s,1H),7.52(dd,J＝7.9,1.6Hz,1H),7.24(td,J＝7.7,1.6Hz,1H),7.20-7.11(m,2H),6.93(s,1H),6.37(m,1H),6.18(dd,J＝16.9,2.1Hz,1H),5.74-5.66(m,1H),3.75(s,3H),3.13(s,3H),3.01(s,3H),2.84(bs,2H),2.65(s,3H),2.37-2.07(m,8H).MS:ESI m/z 625.1[M+H]+,HPLC纯度：97.9％.
实施例9.N-(2-(4-(二甲基氨基)哌啶-1-基)-4-甲氧基-5-((4-((2-(N-甲基甲磺酰氨基)苯基)氨基)噻吩并[3,2-d]嘧啶-2-基)氨基)苯基)丙烯酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ10.05(s,1H),8.74(s,1H),8.35(s,1H),8.03(d,J＝5.3Hz,1H),8.00(dd,J＝8.1,1.6Hz,1H),7.70(s,1H),7.52(dd,J＝7.9,1.6Hz,1H),7.24(td,J＝7.7,1.6Hz,1H),7.20-7.11(m,2H),6.93(s,1H),6.37(m,1H),6.18(dd,J＝16.9,2.1Hz,1H),5.74-5.66(m,1H),3.72(s,3H),3.14(s,3H),3.06(s,3H),3.00(d,J＝11.2Hz,2H),2.62(dd,J＝12.4,10.2Hz,2H),2.19(s,7H),1.80(d,J＝11.4Hz,2H),1.65(q,J＝11.3Hz,2H).MS:ESI m/z650.0[M+H]+,HPLC纯度：98.1％.
实施例10.N-(5-((5-氯-4-((2-(甲磺酰氨基)苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz；DMSO-d6):δ(ppm):10.02(1H,br s),8.35-8.31(2H,m),8.26(1H,s)8.21-8.19(1H,d),8.09(1H,s),7.53-7.50(1H,dd),7.12-7.04(2H,m),6.95(1H,s),6.37(1H,br s),6.18-6.14(1H,dd),5.72-5.68(1H,dd),3.72(3H,s),3.14(3H,s),2.86(2H,m),2.66(3H,s),2.19(8H,br s).[M+H]+:m/z 588.20,实测589.1 HPLC纯度：98.2％
实施例11.N-(5-((5-氯-4-((5-(N-甲基甲磺酰氨基)喹喔啉-6-基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ9.51(d,J＝7.3Hz,2H),9.43(s,1H),9.34(d,J＝7.5Hz,1H),8.58(d,J＝7.5Hz,1H),8.52(s,1H),7.58(d,J＝7.5Hz,1H),7.53(d,J＝7.3Hz,2H),6.41(s,1H),6.34(dd,J＝16.7,10.0Hz,1H),6.03(dd,J＝10.0,3.1Hz,1H),5.93(dd,J＝16.7,3.1Hz,1H),3.72(s,3H),3.14(s,3H),3.05(s,3H),2.86(m,2H),2.66(s,3H),2.19(m,8H).MS:ESI m/z 655.1[M+H]+,HPLC纯度：98.7％
实施例12.N-(5-((5-氯-4-((5-(甲磺酰氨基)喹喔啉-6-基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ9.50(d,J＝7.3Hz,2H),9.43(s,1H),9.36(d,J＝7.5Hz,1H),8.58(d,J＝7.5Hz,1H),8.52(s,1H),7.56(d,J＝7.5Hz,1H),7.53(d,J＝7.3Hz,2H),6.41(s,1H),6.34(dd,J＝16.7,10.0Hz,1H),6.03(dd,J＝10.0,3.1Hz,1H),5.93(dd,J＝16.7,3.1Hz,1H),3.72(s,3H),3.12(s,3H),2.86(m,2H),2.66(s,3H),2.19(m,8H).MS:ESI m/z 641.0[M+H]+,HPLC纯度：97.3％.
实施例13.N-(5-((5-氯-4-((5-氟-2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ9.49(s,1H),9.42(d,J＝8.2Hz,2H),8.52(s,1H),7.75(dd,J＝8.0,1.5Hz,1H),7.54(s,1H),7.31(dd,J＝7.5,5.0Hz,1H),6.93-6.84(m,1H),6.41(s,1H),6.34(dd,J＝16.7,10.0Hz,1H),6.03(dd,J＝10.0,3.1Hz,1H),5.93(dd,J＝16.7,3.1Hz,1H),3.72(s,3H),3.14(s,3H),3.05(s,3H),2.86(bs,2H),2.63(s,3H),2.20(m,8H).MS:ESI m/z 621.0[M+H]+HPLC纯度：98.9％.
实施例14.N-(5-((5-氯-4-((5-氟-2-(甲磺酰氨基)苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ9.67(s,1H),9.54(s,1H),9.43(d,J＝2.5Hz,2H),8.52(s,1H),7.56-7.48(m,3H),6.84(ddd,J＝8.0,7.5,1.5Hz,1H),6.41(s,1H),6.34(dd,J＝16.7,10.0Hz,1H),6.03(dd,J＝10.0,3.1Hz,1H),5.93(dd,J＝16.7,3.1Hz,1H),3.70(s,3H),3.16(s,3H),2.83(bs,2H),2.63(s,3H),2.18(m,8H).MS:ESI m/z 607.0[M+H]+HPLC纯度：98.7％.
实施例15. 2-((5-丙烯酰胺基-4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基苯基)氨基)-4-((2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-5-羧酸异丙酯的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ10.22(s,1H),9.59-9.48(m,2H),8.84(s,1H),7.54(s,1H),7.18(dd,J＝7.4,1.5Hz,1H),7.08-6.99(m,2H),6.95(td,J＝7.1,2.1Hz,1H),6.41(s,1H),6.34(dd,J＝16.7,10.1Hz,1H),6.03(dd,J＝9.9,3.1Hz,1H),5.93(dd,J＝16.7,3.1Hz,1H),5.09(h,J＝6.2Hz,1H),3.81(s,3H),3.26(t,J＝6.8Hz,2H),3.12(s,3H),3.08(s,3H),2.83(s,3H),2.43(m,2H),2.11(s,6H),1.28(d,J＝6.2Hz,6H),MS:ESI m/z 655.0[M+H]+HPLC纯度：98.9％.
实施例16. 2-((5-丙烯酰胺基-4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基苯基)氨基)-4-((2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-5-羧酸环丙酯的制备
最终的化合物是通过上述反应图式4制备的。
1H NMR(400MHz,DMSO-d6)δ10.20(s,1H),9.58-9.47(m,2H),8.82(s,1H),7.54(s,1H),7.18(dd,J＝7.4,1.5Hz,1H),7.08-6.99(m,2H),6.95(td,J＝7.1,2.1Hz,1H),6.41(s,1H),6.34(dd,J＝16.7,10.1Hz,1H),6.03(dd,J＝9.9,3.1Hz,1H),5.93(dd,J＝16.7,3.1Hz,1H),5.06(m,1H),3.79(s,3H),3.26(t,J＝6.8Hz,2H),3.15(s,3H),3.09(s,3H),2.80(s,3H),2.43(m,2H),2.11(s,6H),0.98-0.95(m,2H),0.88-0.85(m,2H),MS:ESI m/z653.0[M+H]+HPLC纯度：98.6％.
实施例17的合成实施例
[反应图式5]
步骤1：合成N-甲基-N-(2-硝基苯基)甲磺酰胺
将1-氟-2-硝基苯(1.0eq.)溶解在乙腈中，在室温下加入碳酸钾(2.0eq.)和N-甲基甲磺酰胺(1.4eq.)。然后，在80℃下搅拌过夜。完成反应后，将温度降至室温，并过滤。滤液在减压下蒸发，得到化合物。没有分离过程，其被用于下一反应。
步骤2：N-(2-氨基苯基)-N-甲基甲磺酰胺的合成
将N-甲基-N-(2-硝基苯基)甲磺酰胺(1.0eq.)溶于甲醇，并加入和乙酸乙酯(1:1)和10％钯/炭(0.2eq.)。在氢气下，搅拌2小时。反应完成后，用铁铝酸四钙过滤，然后减压蒸发滤液。用乙醚和戊烷将其固化并过滤，得到目标化合物。没有分离过程，其被用于下一反应。
步骤3：合成N-(2-((6-氯嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺
将N-(2-氨基苯基)-N-甲基甲磺酰胺(1.0eq.)溶于异丙醇，并在室温下加入2,4,5-三氯吡喃(1.1eq.)和N,N-二异丙基乙胺(2.5eq.)。在80℃下搅拌过夜。完成反应后，减压蒸发，用水和二氯甲烷提取。有机层用2N盐酸清洗。有机层在减压下蒸发，并进行柱色谱分析，得到目标化合物。(50％己烷/乙酸乙酯)
步骤4：合成N-(2-((6-((4-氟-2-甲氧基-5-硝基苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺
将嘧啶衍生物(1.0eq.)溶于异丙醇，在室温下加入苯胺衍生物(1.0eq.)和甲磺酸(1.3eq.)。在80℃下搅拌过夜。反应完成后，减压蒸发，用水和10％甲醇/二氯甲烷混合溶液提取。有机层减压蒸发，进行柱色谱分析，得到目标化合物。(50％己烷/乙酸乙酯)
步骤5：合成N-(2-((6-((4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基-5-硝基苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺
将N-(2-((6-((4-氟-2-甲氧基-5-硝基苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺(1.0eq.)溶于乙腈，在室温下加入碳酸钾(3.0eq.)和胺链(1.2eq.)。通过回流搅拌过夜。完成反应后，将温度降至室温，并进行过滤。滤液在减压下蒸发，得到目标化合物。没有分离过程，其被用于下一反应。
步骤6：合成N-(2-((6-((5-氨基-4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺
将N-(2-((6-((4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基-5-硝基苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺(1.0eq.)溶于1,4-二氧六环，在室温下加入锌(10.0eq.)和氯化铵(10.0eq.)，并搅拌一夜。完成反应后，将温度降至室温，经铁铝酸四钙过滤后，减压蒸发滤液，得到化合物。没有分离过程，其被用于下一反应。
步骤7：合成N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基-5-((6-((2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-4-基)氨基)苯基)丙烯酰胺
将N-(2-((6-((5-氨基-4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺(1.0eq.)溶于四氢呋喃和水中，在0±5℃下加入3-氯丙酰氯(1.2eq.)。在同一温度下，搅拌15分钟。完成反应后，在相同温度下加入氢氧化钠(4.0eq.)。通过提高反应器温度，在65℃下搅拌过夜。反应完成后，减压蒸发除去溶剂，用水和10％甲醇/二氯甲烷混合溶液提取。在减压下蒸发有机层，进行柱色谱分析，得到目标化合物。(10％甲醇/二氯甲烷)
实施例17.N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基-5-((6-((2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-4-基)氨基)苯基)丙烯酰胺
产量：23.0％，白色固体，1H NMR(400MHz,DMSO-d6)δ10.04(s,1H),8.42(s,1H),8.29(s,1H),8.09(d,J＝0.9Hz,1H),8.00(s,1H),7.79(dd,J＝8.2,1.5Hz,1H),7.46(dd,J＝8.0,1.5Hz,1H),7.26(ddd,J＝8.4,7.4,1.6Hz,1H),7.07(td,J＝7.6,1.5Hz,1H),6.93(s,1H),6.34(dd,J＝16.9,10.0Hz,1H),6.19(dd,J＝16.9,2.2Hz,1H),6.04(d,J＝1.1Hz,1H),5.71(dd,J＝10.0,2.2Hz,1H),3.74(s,3H),3.10(s,3H),2.99(s,3H),2.80(t,J＝5.9Hz,2H),2.66(s,3H),2.26(t,J＝5.8Hz,2H),2.16(s,6H).MS:ESI m/z 569.14[M+H]+
实验实施例1：癌细胞生长抑制作用的测量
由于具有EGFR插入突变的肺癌细胞系不能从商业上获得，因此尝试了一种利用位点直接诱变法在野生型EGFR表达载体的每个位点插入3-4个氨基酸的方法。首先，本发明使用了一种载体，在最常发生改变的D770_N771位点加入3个氨基酸的NPG，并使用Ba/F3细胞系来表达这些基因。Ba/F3细胞系是Murine IL3依赖性亲B细胞系，仅在加入IL-3时显示细胞生长，在没有IL-3的情况下，表达致癌突变的EGFR时，具有突变的EGFR依赖性的细胞生长和死亡。因为对突变的EGFR显示有效抑制作用的物质会抑制细胞生长和诱导细胞凋亡，所以通过MTT法分析细胞的抗癌作用。
将预先构建好的1×104个细胞的稳定细胞置于96孔板中并培养过夜，然后以剂量依赖的方式处理实施例中的化合物。72小时后，加入MTT试剂，3小时后，加入终止缓冲液(10％SDS)。培养24小时后，在595nm处读取分析结果，并在每个化合物抑制细胞生长50％的浓度下计算IC50的值。结果在表1中显示为A、B、C和D。在本文中，A表示IC50≤100nM，B表示IC50＝100-300nM，C表示IC50＝300-1,000nM，D表示IC50>1,000nM。作为对照药物，使用奥希替尼。
癌细胞生长抑制作用的实测(GI50)
表1
| 实施例 | EXON 20插入(NPG)Ba/F3细胞 |
| 1 | C |
| 2 | C |
| 3 | C |
| 4 | C |
| 5 | C |
| 6 | C |
| 7 | B |
| 8 | B |
| 9 | B |
| 10 | A |
| 11 | A |
| 12 | A |
| 13 | A |
| 14 | A |
| 15 | A |
| 16 | A |
| 17 | A |
| 奥希替尼 | C |
如表1所示，根据本发明的化合物对表达表皮生长因子受体的EXON 20插入突变的肺癌细胞系表现出优异的活性。特别是，实施例10-17化合物的活性更为出色。另一方面，对照药物奥希替尼的活性则相对较弱。
因此，本发明提出了一种新型的嘧啶衍生物，其可治疗表达表皮生长因子受体EXON 20插入突变的肺癌。
Claims (6)
1.下述化学式1的化合物或其药学上可接受的盐：
[化学式1]
在化学式1中，
A、B、D、E和G是A＝N、B＝C、D＝C、E＝C和G＝N的组合，或A＝N、B＝C、D＝N、E＝C和G＝C的组合，
W是氧或NH，
X和Y分别是CH、氧或氮，
Z1和Z2分别是C1至C4烷基，或分别由碳原子组成并且相互连接以与X和Y一起形成5、6或7元环，
当X或Y是氧时，Z1和Z2分别不存在；或当X或Y不是氧时，Z1和Z2分别是C1至C4烷基，或分别由碳原子组成并且相互连接以与X和Y一起形成5、6或7元环，
R1是C1至C4烷基，
R2是氢，或C1至C4烷基，
R3和R4分别是氢、卤素、OH、OME、OEt、CN、CF3、C1至C4烷基，或相互连接以形成5或6元杂芳环，
R5是氢、卤素、OH、OMe、OEt、CN、CF3或C1至C4烷基，
R6和R7分别是氢、卤素、OH、OMe、OEt、CN、CF3、COOH、COO-C1-4烷基、COO-C1-5环烷基、C1至C4烷基，或相互连接以形成5或6元杂芳环，
R8是氢、卤素、OH、OMe、OEt、CN、CF3或C1至C4烷基，
R9是-C(O)-CH＝CH2或C1至C4烷基，并且
R10不存在或是氢、卤素、C1至C4烷基、OH、OME、OEt、CN、CF3、NMe2、哌嗪、被C1至C3烷基取代的哌嗪、吗啉或被C1至C3烷基取代的吗啉。
2.根据权利要求1所述的化合物或其药学上可接受的盐，其中，所述化合物为：
N-(2-((5-氯-2-((4-((2-(二甲基氨基)乙基)(甲基)氨基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)吡啶-4-基)氨基)苯基)-N-甲磺酸酰胺，
N-(2-((2-((4-((2-(二甲基氨基)乙基)(甲基)氨基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)噻吩并[3,2-d]嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺，
N-(2-((2-((4-(4-(二甲基氨基)哌啶-1-基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)噻吩并[3,2-d]嘧啶-4-基)氨基)苯基)-N-甲氧基甲磺酰胺，
N-(2-((2-((5-(异丙基氨基)-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)噻吩并[3,2-d]嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺，
N-(2-((5-氯-2-((5-(异丙基氨基)-2-甲氧基-4-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺，
N-(2-((5-氯-2-((4-(4-(二甲基氨基)哌啶-1-基)-5-(异丙基氨基)-2-甲氧基苯基)氨基)嘧啶-4-基)氨基)苯基)-N-甲基甲磺酰胺，
N-(4-甲氧基-5-((4-((2-(N-甲基甲磺酰氨基)苯基)氨基)噻吩并[3,2-d]嘧啶-2-基)氨基)-2-(4-(4-甲基哌嗪-1-基)哌啶-1-基)苯基)丙烯酰胺，
N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基-5-((4-((2-(N-甲基甲磺酰氨基)苯基)氨基)噻吩并[3,2-d]嘧啶-2-基)氨基)苯基)丙烯酰胺，
N-(2-(4-(二甲基氨基)哌啶-1-基)-4-甲氧基-5-((4-((2-(N-甲基甲磺酰氨基)苯基)氨基)噻吩并[3,2-d]嘧啶-2-基)氨基)苯基)丙烯酰胺，
N-(5-((5-氯-4-((2-(甲磺酰氨基)苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺，
N-(5-((5-氯-4-((5-(N-甲基甲磺酰氨基)喹喔啉-6-基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺，
N-(5-((5-氯-4-((5-(甲磺酰氨基)喹喔啉-6-基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺，
N-(5-((5-氯-4-((5-氟-2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺，
N-(5-((5-氯-4-((5-氟-2-(甲磺酰氨基)苯基)氨基)嘧啶-2-基)氨基)-2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基苯基)丙烯酰胺，
2-((5-丙烯酰胺基-4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基苯基)氨基)-4-((2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-5-羧酸异丙酯，
2-((5-丙烯酰胺基-4-((2-(二甲基氨基)乙基)(甲基)氨基)-2-甲氧基苯基)氨基)-4-((2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-5-羧酸环丙酯，或
N-(2-((2-(二甲基氨基)乙基)(甲基)氨基)-4-甲氧基-5-((6-((2-(N-甲基甲磺酰氨基)苯基)氨基)嘧啶-4-基)氨基)苯基)丙烯酰胺。
3.一种组合物，包含权利要求1或权利要求2所述的化合物或其药学上可接受的盐，以及药学上可接受的载体。
4.一种用于治疗或预防肺癌的药物组合物，其特征在于，包括权利要求1或权利要求2所述的化合物或其药学上可接受的盐作为活性成分。
5.根据权利要求4所述的用于治疗或预防肺癌的药物组合物，其中，所述肺癌是表达表皮生长因子受体突变的肺癌。
6.根据权利要求4所述的用于治疗或预防肺癌的药物组合物，其中，所述突变是EXON20插入突变。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20190073345 | 2019-06-20 | ||
| KR10-2019-0073345 | 2019-06-20 | ||
| PCT/KR2020/007982 WO2020256477A1 (ko) | 2019-06-20 | 2020-06-19 | 암 세포 성장을 억제하는 피리미딘 유도체 및 이의 의약 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114008028A true CN114008028A (zh) | 2022-02-01 |
| CN114008028B CN114008028B (zh) | 2024-07-09 |
Family
ID=
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120047208A (ko) * | 2009-05-05 | 2012-05-11 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| WO2014124230A2 (en) * | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
| CN106187915A (zh) * | 2015-05-27 | 2016-12-07 | 上海翰森生物医药科技有限公司 | 具有alk与egfr双重活性的抑制剂及其制备方法和应用 |
| US20170226065A1 (en) * | 2014-08-03 | 2017-08-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Potent dual brd4-kinase inhibitors as cancer therapeutics |
| US20190152969A1 (en) * | 2014-11-05 | 2019-05-23 | Inventisbio Shanghai Ltd | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof |
| CN114105887A (zh) * | 2021-09-16 | 2022-03-01 | 沈阳药科大学 | 一种氨基嘧啶衍生物及其制备方法和用途 |
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20120047208A (ko) * | 2009-05-05 | 2012-05-11 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| CN102482277A (zh) * | 2009-05-05 | 2012-05-30 | 达纳-法伯癌症研究所有限公司 | 表皮生长因子受体抑制剂及治疗障碍的方法 |
| WO2014124230A2 (en) * | 2013-02-08 | 2014-08-14 | Celgene Avilomics Research, Inc. | Erk inhibitors and uses thereof |
| US20170226065A1 (en) * | 2014-08-03 | 2017-08-10 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Potent dual brd4-kinase inhibitors as cancer therapeutics |
| US20190152969A1 (en) * | 2014-11-05 | 2019-05-23 | Inventisbio Shanghai Ltd | Pyrimidine or pyridine compounds, preparation method therefor and pharmaceutical uses thereof |
| CN106187915A (zh) * | 2015-05-27 | 2016-12-07 | 上海翰森生物医药科技有限公司 | 具有alk与egfr双重活性的抑制剂及其制备方法和应用 |
| CN114105887A (zh) * | 2021-09-16 | 2022-03-01 | 沈阳药科大学 | 一种氨基嘧啶衍生物及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP7330546B2 (ja) | 2023-08-22 |
| MX2021015543A (es) | 2022-04-25 |
| US20220227781A1 (en) | 2022-07-21 |
| WO2020256477A1 (ko) | 2020-12-24 |
| EP3988542A4 (en) | 2023-06-28 |
| BR112021025764A2 (pt) | 2022-02-01 |
| JP7330546B6 (ja) | 2024-02-21 |
| KR102510072B1 (ko) | 2023-03-14 |
| EP3988542A1 (en) | 2022-04-27 |
| AU2020296620B2 (en) | 2023-07-13 |
| AU2020296620A1 (en) | 2022-02-17 |
| KR20200145833A (ko) | 2020-12-30 |
| CA3143919A1 (en) | 2020-12-24 |
| JP2022538014A (ja) | 2022-08-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102510072B1 (ko) | 암 세포 성장을 억제하는 피리미딘 유도체 및 이의 의약 용도 | |
| WO2020259432A1 (zh) | Kras-g12c抑制剂 | |
| TWI804933B (zh) | 用作cdk7激酶抑制劑的化合物及其應用 | |
| CN110582483A (zh) | 含邻氨基杂芳环炔基的化合物及其制备方法和用途 | |
| KR100737090B1 (ko) | 축합 이미다졸륨 유도체 | |
| WO2020233641A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
| JP2023175689A (ja) | 置換ピロロトリアジン系化合物およびその医薬組成物並びにそれらの使用 | |
| CN111356456A (zh) | 2-芳基磺酰胺基-iV-芳基乙酰胺衍生的Stat3抑制剂 | |
| CA3016830A1 (en) | Crystalline forms of mesylate salt of pyridinyl amino pyrimidine derivative, preparation methods therefor, and applications thereof | |
| WO2022083657A1 (zh) | 取代苯并或吡啶并嘧啶胺类抑制剂及其制备方法和应用 | |
| TW202309007A (zh) | 化合物及其作為ｃｄ３８抑制劑的用途 | |
| JP2021512873A (ja) | Ｔｎｉｋを阻害するための化合物及びその医学的使用 | |
| CA3090876C (en) | Dioxinoquinoline compounds, preparation method and uses thereof | |
| CN115322158B (zh) | 作为krasg12c蛋白抑制剂的取代喹唑啉类化合物 | |
| EP3130588B1 (en) | Polysubstituted pyridine compound, preparation method, use and pharmaceutical composition | |
| CN113402543A (zh) | 丁苯酞开环衍生物及其制备方法和用途 | |
| KR20200123184A (ko) | 증식이상 장애를 치료하기 위한 물질 및 방법 | |
| CN114008028B (zh) | 抑制癌细胞生长的嘧啶衍生物及其医药用途 | |
| TW202317532A (zh) | Aak1抑制劑及其用途 | |
| CN114206864B (zh) | 喹唑啉-2.4-二酮衍生物作为parp抑制剂 | |
| KR20210032093A (ko) | Ｅｇｆｒ 돌연변이 키나제 성장 억제 효과를 나타내는 피리미딘 유도체 및 이의 의약 용도 | |
| RU2792849C1 (ru) | Производное пиримидина, подавляющее рост раковой клетки, и его медицинское применение | |
| WO2021233133A1 (zh) | 用作ret激酶抑制剂的化合物及其应用 | |
| KR101920163B1 (ko) | 항암용 약학 조성물 | |
| JP2003128548A (ja) | 縮合イミダゾリウム誘導体を含む医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |